- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00875342
Imaginal Exposure & D-Cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)
D-cycloserine Enhanced Imaginal ExposureTherapy for Posttraumatic Stress Disorder (PTSD)
This study proposes to evaluate the effects of D-cycloserine (DCS) combined with cognitive-behavioral treatment with exposure therapy in a sample of patients who developed posttraumatic stress disorder (PTSD) as a consequence of various traumas (e.g., motor vehicle and accidents, burns and other injuries, combat, World Trade Center attack, etc.). In addition, this study hopes to determine whether a common human genetic single nucleotide polymorphism (SNP) in a growth factor, brain derived neurotrophic factor, BDNF SNP (Val66Met), predicts treatment response to PTSD.
Patients living in areas that are not geographically proximal to the Weill-Cornell Medical Center New York City campus will receive cognitive behavioral therapy using telemedicine (videoconferencing technology).
Overall, this study aims 1) to determine if subjects administered DCS show a significantly larger decrease in symptoms of PTSD as compared to those administered a placebo, 2) to determine if subjects administered DCS show a decrease in PTSD symptomatology significantly earlier (as measured by weeks) than those administered a placebo, 3) to determine if differences in symptomatology are evident at a 6-month follow-up and indicate long-term differences between groups, 4) to determine if the BDNF SNP predicts treatment response, 5)to determine if it is feasible and acceptable to provide imaginal exposure (IE) therapy for PTSD using videoconferencing technology.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- English-speaking adults
- Age 18-70
- Survivor of a variety of traumas (e.g., motor vehicle and accidents, burns and others injuries, combat, World Trade Center attack, etc.)
- Diagnosed with PTSD
- In good health. For persons with chronic injuries/conditions related to their accidents, "good health" is defined as the injury being in a state of stabilization and able to attend weekly outpatient sessions.
Exclusion Criteria:
- Current organic mental disorder
- Schizophrenia or symptoms of psychosis/delusions
- Bipolar disorder
- Current substance abuse or dependence
- Active suicidal/homicidal ideation, intent, or plan
- Use of pacemaker
- Significant health impairment, including renal disease
- Taking oral anticoagulant medication, ethionamide (Trecator-SC), isoniazid (INH), or anti-depressant medication
- Hypersensitivity to cycloserine
- History of seizures
- Pregnant or currently trying to conceive, or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Sugar pill
|
2. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)
|
Experimental: D-cycloserine
100 mg on days of therapy session
|
1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptoms of Posttraumatic Stress Disorder-Clinician Administered PTSD Scale (CAPS)
Time Frame: Immediately after the intervention, an average of 6 months
|
Clinician Administered PTSD Scale (CAPS).
Total CAPS severity score range is 0-136.
Higher values represent a worse outcome (i.e.
greater severity of posttraumatic symptoms).
|
Immediately after the intervention, an average of 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: JoAnn Difede, PhD, Weill Medical College of Cornell University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0802009646
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Posttraumatic Stress Disorder
-
University Hospital, ToursCompletedPostTraumatic Stress DisorderFrance
-
The University of Texas Health Science Center at...University of Pennsylvania; Brooke Army Medical Center; C.R.Darnall Army Medical... and other collaboratorsCompletedPosttraumatic Stress Disorder (PTSD)United States
-
Icahn School of Medicine at Mount SinaiCompletedPosttraumatic Stress Disorder (PTSD)United States
-
Berlin Center for the Treatment of Torture VictimsCompletedPosttraumatic Stress Disorder (PTSD)Germany
-
TEMPVA Research Group, Inc.C.R.Darnall Army Medical Center; VA Boston Healthcare System; Central Texas Veterans...UnknownPosttraumatic Stress Disorder, Combat-relatedUnited States
-
VA Office of Research and DevelopmentCompletedPosttraumatic Stress Disorder (PTSD)United States
-
Michael E. DeBakey VA Medical CenterSouth Central VA Mental Illness Research, Education & Clinical CenterCompletedPosttraumatic Stress Disorder (PTSD)United States
-
VA Office of Research and DevelopmentCompletedPosttraumatic Stress Disorder (PTSD)United States
-
VA Office of Research and DevelopmentCompleted
-
Yale UniversityNational Center for PTSDCompletedPosttraumatic Stress Disorder (PTSD)United States
Clinical Trials on DCS
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Not yet recruitingEpilepsy | Working MemoryUnited States
-
Queen Mary University of LondonBarts & The London NHS TrustCompletedTraumatic Brain Injury | Intracranial HypertensionUnited Kingdom
-
Codman & ShurtleffCompleted
-
LanZhou UniversityUnknown
-
Hamilton Health Sciences CorporationMcMaster University; Canadian Breast Cancer Research Alliance; Ontario Cancer...CompletedBreast NeoplasmsCanada
-
University of ManitobaRecruitingSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Paraplegia, Spinal | Paraplegia, IncompleteCanada
-
IRCCS National Neurological Institute "C. Mondino...CompletedParkinson Disease | Pisa SyndromeItaly
-
University of Castilla-La ManchaUniversidad Rey Juan Carlos; Hospital Nacional de Parapléjicos de ToledoCompletedPain | Transcranial Direct Current StimulationSpain
-
National Taiwan University HospitalUnknown
-
Mustafa Khasraw, MBChB, MD, FRCP, FRACPCompletedGlioblastoma | Glioblastoma Multiforme | Giant Cell Glioblastoma | Astrocytoma, Grade IVUnited States